SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Fiddler who wrote (10086)6/25/1998 5:06:00 PM
From: Diamondcutter  Read Replies (1) | Respond to of 23519
 
Lower margins doesn't necessarily mean negative margins. Lower profit margins are likely relative to the variable cost to produce a unit, leaving the fixed costs of the new facility to be covered by gross profits on x number of units shipped. With the higher margined US production limited until the FDA approval, the international sales are not enough to cover the overhead. This should (or put differently, had better) change once domestic shipments of size begin again and (hopefully) scripts pick up again. Viagra scripts for the last few weeks were encouraging.

Diamondcutter



To: Fiddler who wrote (10086)6/25/1998 5:13:00 PM
From: Mkilloran  Read Replies (2) | Respond to of 23519
 
Fiddler...things are falling inplace for a good 3rd qtr......
With overseas distributers expertize and lower cost in the new plant look for good 3rd qtr earnings....FULL distribution to ALL countries approved can now start....More countries can now come online and be supplied without capacity constraints........................All at a better profit margin...

The 3rd qtr will be fun for the longs...............


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News